WO2018012479A1 - Procédé de préparation de population de cellules arborescentes - Google Patents

Procédé de préparation de population de cellules arborescentes Download PDF

Info

Publication number
WO2018012479A1
WO2018012479A1 PCT/JP2017/025207 JP2017025207W WO2018012479A1 WO 2018012479 A1 WO2018012479 A1 WO 2018012479A1 JP 2017025207 W JP2017025207 W JP 2017025207W WO 2018012479 A1 WO2018012479 A1 WO 2018012479A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell population
cells
cell
group
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/025207
Other languages
English (en)
Japanese (ja)
Inventor
結 原田
米満　吉和
経義 斎藤
姿宣 醍醐
亮平 小口
今日子 山本
創 江口
伊藤　亨
綾 和田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Techno Glass Co Ltd
AGC Inc
Gaia Biomedicine Inc
Original Assignee
Asahi Glass Co Ltd
AGC Techno Glass Co Ltd
Gaia Biomedicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd, AGC Techno Glass Co Ltd, Gaia Biomedicine Inc filed Critical Asahi Glass Co Ltd
Publication of WO2018012479A1 publication Critical patent/WO2018012479A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Definitions

  • the present invention relates to a method for culturing dendritic cells. Specifically, the present invention relates to a method for culturing dendritic cells, which comprises using a culture vessel coated with a novel coating agent.
  • Dendritic cells can stimulate or suppress the immune system, including both acquired and innate immunity, as antigen-presenting cells. Therefore, the patient's immune system is controlled by transplanting dendritic cells previously treated outside the body to present specific antigens related to cancer, infectious diseases, autoimmune diseases, allergic diseases, etc. Dendritic cell transplantation therapy has been attempted. However, such dendritic cell transplantation therapy requires large amounts of dendritic cells. For example, according to studies using experimental animal model systems for skin tumors and lung metastases, the optimal number of dendritic cells to be transplanted in any model system is at least 10 6 per 30 g body weight of experimental animals. The result that it was was obtained (nonpatent literature 1 and 2). This corresponds to at least about 10 9 dendritic cells in a single dose per patient when converted to humans. However, clinically, only 10 6 to 10 8 dendritic cells can be collected from one person even when apheresis is performed.
  • the method for culturing dendritic cells described in Patent Document 1 is a very excellent method for obtaining a large amount of dendritic cells from blood cells collected from a subject in order to perform dendritic cell transplantation therapy. is there.
  • the present inventors examined a more efficient method for culturing dendritic cells from various angles based on the method described in Patent Document 1.
  • the present inventors examined a more efficient method for culturing dendritic cells from various angles based on the method described in Patent Document 1. Then, the inventors of the present invention surprisingly more efficiently than the method described in Patent Document 1 by using a culture vessel coated with a novel coating agent in examining various culture conditions. Thus, the inventors have found that dendritic cells can be cultured, and have completed the present invention.
  • the present invention in one embodiment, is a method for preparing a dendritic cell population, (A) separating the mononuclear cell population from the collected blood cell population; (B): removing a cell population expressing CD3 on the cell surface from the mononuclear cell population separated in the step (a); (C): a cell culture vessel having a coating layer formed from a fluoropolymer containing a polymer unit based on a monomer having a bioaffinity group from the mononuclear cell population obtained in step (b). And culturing in a medium containing GM-CSF and SCF.
  • the fluorine atom content in the fluoropolymer is 5 to 60% by mass
  • the coating layer has a thickness of 1 nm to 100 ⁇ m.
  • the cell population expressing CD3 on the cell surface is a T cell population.
  • the step (b) further comprises a cell population expressing CD19 on the cell surface from the mononuclear cell population separated in the step (a), and CD56 on the cell surface. It is a step of removing a cell population to be expressed.
  • the cell population expressing CD19 on the cell surface is a B cell population, and the cell population expressing CD56 on the cell surface is an NK cell population. To do.
  • the cell population cultured in the step (c) is further cultured in a medium containing GM-CSF and IL-4.
  • the culture period in step (c) is 2 to 5 weeks, and the culture period in step (d) is 2 to 14 days.
  • the method includes (e): stimulating the cell population cultured in the step (d) with OK-432 or the like.
  • the collected blood cell population is a collected blood cell population derived from peripheral blood, umbilical cord blood, bone marrow and / or lymph node.
  • the collected blood cell population is a blood cell population collected from the collected peripheral blood by an apheresis method.
  • FIG. 1 shows a schematic diagram of the cell culture process (New Coat, MPC, Adhesion) performed in the examples of the present application.
  • FIG. 2 shows the composition of the mononuclear cell population after separation by Ficoll, and the mononuclear cell population after further removal of CD3-expressing cells, CD19-expressing cells, and CD56-expressing cells by flow cytometry. Results are shown.
  • FIG. 3 shows the change in the number of cells under each culture condition (Day 0 to 29).
  • FIG. 4 shows changes in the number of CD11c positive cells under each culture condition (Day 0 to 29).
  • FIG. 5 shows the amplification factor of the number of CD11c positive cells at Day 0 to 29 in each culture condition.
  • FIG. 6 shows the expression of cell surface markers in the final product at the end of the culture (CD11c, HLA-ABC, CD83).
  • FIG. 7 shows the expression of cell surface markers in the final product at the end of culture (CD80, CD86, HLA-DR).
  • the origin of the blood cell population used in step (a) of the method of the present invention may be, for example, collected peripheral blood, collected bone marrow, collected lymph nodes, or collected umbilical cord blood.
  • the present invention is not limited to these, and blood cell populations derived from various origins can be used.
  • an embryonic stem cell, an adult stem cell, or a hematopoietic stem cell derived from an induced pluripotent stem (iPS) cell (or a blood cell population prepared from the hematopoietic stem cell) or the like is used in the step (a ) In “collected blood cell population”.
  • the origin of the blood cell population used in step (a) of the method of the present invention is preferably peripheral blood.
  • the method for separating the mononuclear cell population from the blood cell population is not limited, and those skilled in the art can implement it in various ways.
  • a mononuclear cell population can be separated from a blood cell population by density gradient centrifugation.
  • the method for removing the cell population expressing CD3 on the cell surface from the mononuclear cell population is not limited, and those skilled in the art can implement it in various ways.
  • Dyna3 by Dynale (trademark) sold by Life Technologies, CliniMACS (trademark) from Miltenyi Biotech and CD3 microbeads are used to place CD3 on the cell surface.
  • Cell populations expressed in can be removed.
  • a cell population that expresses CD3 on the cell surface may be removed using flow cytometry or other immunological separation means, for cell populations that express CD3 on the cell surface (eg, T cells).
  • Specific binding partners may be utilized to remove by selectively injuring or killing only the cell population that expresses CD3 on the cell surface.
  • a cell population expressing CD19 on the cell surface and a cell population expressing CD56 on the cell surface are simply used. It may be removed from the nucleus population.
  • a method for removing a cell population that expresses CD19 on the cell surface and a method for removing a cell population that expresses CD56 on the cell surface are not limited, and those skilled in the art can implement them in various ways.
  • a cell population that expresses CD19 on the cell surface and a cell population that expresses CD56 on the cell surface can be removed using CD19 microbeads or CD56 microbeads manufactured by Miltenyi Biotech.
  • the cell population expressing CD19 on the cell surface and the cell population expressing CD56 on the cell surface may be removed using flow cytometry or other immunological separation means, and CD19 is expressed on the cell surface.
  • CD19 is expressed on the cell surface and CD56 is expressed on the cell surface Only cell populations that do so may be removed by selectively injuring or killing them.
  • step (c) cells expressing CD3 from the mononuclear cell population on the cell surface
  • the removal of the population is not simply to remove lymphocytes and enrich the mononuclear cell population.
  • a mononuclear cell population is cultured in a medium to which a cytokine cocktail containing GM-CSF and SCF is added, the proliferation of T cells is significantly promoted rather than that of dendritic cells themselves, A cell population with a low proportion of dendritic cells is formed.
  • a culture vessel coated with a coating agent comprising a fluoropolymer having a polymer unit based on a monomer having a bioaffinity group is prepared from the mononuclear cell population prepared by the above method.
  • Culture By culturing a mononuclear cell population using this container, for example, a cell low adsorption culture container coated with a non-fluorine compatible polymer coating containing 2-methacryloyloxyethyl phosphorylcholine (MPC), or by corona discharge treatment.
  • MPC 2-methacryloyloxyethyl phosphorylcholine
  • dendritic cells can be prepared extremely efficiently. Yes (see examples in this application).
  • An example of such a culture vessel is EZ-BindShut (registered trademark) SP (manufactured by AGC Techno Glass Co., Ltd.).
  • a preferred bioaffinity group is selected from the group consisting of the following groups (1), (2) and (3) from the viewpoint of easily forming a coating layer having a high protein adsorption preventing effect. At least one is preferred.
  • the group (1) alone, or either one or both of the group (2) and the group (3) are preferable from the viewpoint that an effect of preventing protein adsorption is easily obtained, and the group (1), Any one of group (2) or group (3) is particularly preferred.
  • the fluoropolymer (A) is excellent in biocompatibility when it contains the groups (1) to (3).
  • n is an integer of 1 to 10
  • m is an integer of 1 to 100 when the group (1) is contained in the side chain in the fluoropolymer (A), and is contained in the main chain.
  • R 1 to R 3 are each independently an alkyl group having 1 to 5 carbon atoms
  • a is an integer of 1 to 5
  • b is an integer of 1 to 5.
  • R 4 and R 5 are each independently an alkyl group having 1 to 5 carbon atoms
  • X ⁇ is the following group (3-1) or the following group (3-2)
  • c is 1 to 20 is an integer
  • d is an integer of 1 to 5.
  • the group (1) has high mobility in blood or the like, and it is difficult to adsorb proteins to be adsorbed on the surface of the coating layer.
  • the group (1) may be contained in the main chain of the fluoropolymer (A) or in the side chain.
  • n is preferably an integer of 1 to 6 and particularly preferably an integer of 1 to 4 from the viewpoint that protein is difficult to adsorb.
  • the group (1) may be linear or branched.
  • the group (1) is preferably linear because it has a higher protein adsorption inhibitory effect.
  • M in the group (1) is preferably from 1 to 40, particularly preferably from 1 to 20, from the viewpoint of excellent water resistance when the group (1) is contained in the side chain of the fluoropolymer (A).
  • M in the group (1) is preferably from 5 to 300, particularly preferably from 10 to 200, from the viewpoint of excellent water resistance when the group (1) is contained in the main chain of the fluoropolymer (A).
  • m is 2 or more
  • (C n H 2n O) of the group (1) may be one kind or two or more kinds. In the case of two or more types, the arrangement may be random, block, or alternating.
  • n is 3 or more, it may be a straight chain structure or a branched structure.
  • the group (1) of the fluoropolymer (A) may be one type or two or more types.
  • Group (2) has a strong affinity for phospholipids in blood, but has a weak interaction force with plasma proteins. Therefore, by using the fluoropolymer (A) having the group (2), for example, in blood, phospholipid is preferentially adsorbed on the coating layer, and the phospholipid self-assembles to form an adsorption layer. It is thought that it is done. As a result, since the surface has a structure similar to the vascular endothelial surface, adsorption of proteins such as fibrinogen is suppressed.
  • the group (2) is preferably contained in the side chain of the fluoropolymer (A).
  • R 1 to R 3 in the group (2) are each independently an alkyl group having 1 to 5 carbon atoms.
  • an alkyl group having 1 to 4 carbon atoms is preferable, and a methyl group is Particularly preferred.
  • a is an integer of 1 to 5, preferably an integer of 2 to 5 and particularly preferably 2 from the viewpoint of availability of raw materials.
  • b is an integer of 1 to 5, preferably an integer of 1 to 4 and particularly preferably 2 from the viewpoint that protein is difficult to adsorb.
  • the group (2) of the fluoropolymer (A) may be one type or two or more types.
  • Group (3) By using the fluoropolymer (A) having the group (3), protein adsorption is suppressed for the same reason as in the case of using the fluoropolymer (A) having the group (2).
  • the group (3) is preferably contained in the side chain of the fluoropolymer (A).
  • R 4 and R 5 in the group (3) are each independently an alkyl group having 1 to 5 carbon atoms, preferably an alkyl group having 1 to 4 carbon atoms, and particularly preferably a methyl group, from the viewpoint that protein is difficult to adsorb.
  • C in the group (3) is an integer of 1 to 20, preferably an integer of 1 to 15, more preferably an integer of 1 to 10, from the viewpoint that the fluoropolymer (A) is excellent in flexibility.
  • d is an integer of 1 to 5, preferably an integer of 1 to 4, and particularly preferably 1, from the viewpoint that protein is difficult to adsorb.
  • a preferred fluorinated polymer is any one of the following 1) to 3). 1) The unit (m1) derived from the monomer represented by the following formula (m1), the unit (m2) derived from the monomer represented by the following formula (m2), and the following formula (m3) And a fluorine-containing polymer having at least one selected from the group consisting of units derived from the monomer (m3).
  • R 6 is a hydrogen atom, a chlorine atom or a methyl group, e is an integer of 0 to 3 and R 7 and R 8 are each independently a hydrogen atom, a fluorine atom or a trifluoromethyl group
  • R f1 is a perfluoroalkyl group having 1 to 20 carbon atoms
  • R 9 is a hydrogen atom, a chlorine atom or a methyl group
  • Q 1 is —C ( ⁇ O) —O— or C ( ⁇ O) —NH—
  • R 1 to R 3 are each independently an alkyl group having 1 to 5 carbon atoms, a is an integer of 1 to 5, b is an integer of 1 to 5, and R 10 is hydrogen.
  • Q 2 is —C ( ⁇ O) —O— or C ( ⁇ O) —NH—
  • R 4 and R 5 are each independently an alkyl having 1 to 5 carbon atoms.
  • a group, X - is a group represented by the group or the following formula represented by the following formula (3-1) (3-2), c is an integer of 1 to 20 Ri, d is an integer of 1 to 5.)
  • R 6 is a hydrogen atom, a chlorine atom or a methyl group, e is an integer of 0 to 3 and R 7 and R 8 are each independently a hydrogen atom, a fluorine atom or a trifluoromethyl group
  • R f1 is a perfluoroalkyl group having 1 to 20 carbon atoms
  • R 11 is a hydrogen atom, a chlorine atom or a methyl group
  • Q 3 is —COO— or COO (CH 2 ) h —NHCOO—
  • H is an integer of 1 to 4
  • R 12 is a hydrogen atom or (CH 2 ) i -R 13 (wherein R 13 is an alkoxy group having 1 to 8 carbon atoms, a hydrogen atom, a fluorine atom, A trifluoromethyl group, a hydroxy group or a cyano group, i is an integer of 1 to 25)
  • f is an integer of 1 to 10
  • g is an integer of 1 to 100
  • R 16 is a hydrogen atom, a chlorine atom or a methyl group
  • Q 5 is a single bond or a divalent organic group
  • R 17 is an etheric oxygen atom between the carbon atoms.
  • a polyfluoroalkyl group having 1 to 6 carbon atoms, ⁇ is an integer of 5 to 300, and ⁇ is an integer of 1 to 20.
  • the fluorine atom content in the fluoropolymer can be, for example, 5 to 60% by mass, preferably 10 to 50% by mass, and more preferably 15 to 40% by mass. Further, the ratio P represented by the following formula is more preferably 0.1 to 4.5% by mass.
  • (Ratio P) [(Ratio of units having a biocompatible group to all units of fluoropolymer (mass%)) / (Fluorine atom content of fluoropolymer (mass%))] ⁇ 100
  • the thickness of the coating layer can be, for example, 1 nm to 100 ⁇ m, preferably 5 nm to 50 ⁇ m, and more preferably 10 nm to 10 ⁇ m.
  • the medium for culturing cells includes, in addition to IMDM medium, MEM, DMEM, RPMI-1640, and X-VIVO15 medium, but is not limited thereto, and is a medium suitable for the growth of blood cells.
  • Fetal calf serum may be added to these media.
  • the concentration of fetal calf serum may be 5-20%, more preferably 10%.
  • human AB serum available from BioWhittaker et al. Or donated human serum albumin available from Japanese Red Cross may be added. Human AB serum is preferably added at a concentration of 0 to 15%, and blood donated human serum albumin is preferably added at a concentration of 0 to 10%.
  • the method of the present invention includes a step of culturing cells using a medium containing GM-CSF and SCF.
  • the medium containing GM-CSF and SCF contains GM-CSF and SCF, but may be a medium substantially free of other cytokines.
  • the method of the present invention may comprise culturing cells using a medium comprising GM-CSF and IL-4.
  • the medium containing GM-CSF and IL-4 may be a medium containing GM-CSF and IL-4 but not SCF, and also containing GM-CSF and IL-4.
  • a medium substantially free of cytokines other than these may be used.
  • ⁇ Step (e)> In the method of the present invention, OK-432, TNF- ⁇ , IL-1 ⁇ , IL-6 are used after the culture step for amplifying dendritic cells in order to allow the amplified dendritic cells to acquire T cell stimulating ability. Stimulating with a pro-inflammatory mediator such as PGE 2 (preferably OK-432) may further be included.
  • a pro-inflammatory mediator such as PGE 2 (preferably OK-432) may further be included.
  • the cytokine added to the medium preferably has a human amino acid sequence, and is preferably produced by recombinant DNA technology for safety.
  • the concentration of GM-CSF in the medium may range from 1 to 500 ng / mL, 1 to 200 ng / mL or 1 to 100 mg / mL, more preferably 2 to 300 ng / mL, 5 to 200 ng / mL, It may range from 10 to 150 ng / mL, 20 to 120 ng / mL or 30 to 100 ng / mL.
  • the concentration of SCF or IL-4 in the medium may range from 0.5 to 500 ng / mL, 0.5 to 100 ng / mL or 0.5 to 50 ng / mL, more preferably 1 to 300 ng / mL. It may range from mL, 2 to 200 ng / mL, 5 to 100 ng / mL, 10 to 70 ng / mL, 20 to 60 ng / mL or 25 to 50 ng / mL.
  • the medium substantially not containing a certain cytokine may be, for example, a medium containing the cytokine within a range not significantly exceeding the concentration of the cytokine in normal serum. More specifically, in a medium containing the cytokine at 3 times or less, 2 times or less, 1 time or less, 1/2 or less, 1/3 or less, or 1/5 or less of the concentration of the cytokine in normal serum. It may be.
  • the cytokine is 50 ng / mL or less, 40 ng / mL or less, 30 ng / mL or less on the condition that it behaves substantially the same as the behavior of dendritic cells or their precursor cells when the concentration of the cytokine is 0. , 20 ng / mL or less, 10 ng / mL or less, 5 ng / mL or less, 3 ng / mL or less, or 1 ng / mL or less.
  • dendritic cell progenitor cells grown in a medium containing GM-CSF and SCF can be changed to a medium containing GM-CSF and IL-4 to change the subset of dendritic cells.
  • cells that grow in a medium containing GM-CSF and SCF are cells that are determined to differentiate into dendritic cells at any time by GM-CSF and IL-4. Therefore, switching from a medium containing GM-CSF and SCF to a medium containing GM-CSF and IL-4 may be performed at any time after the start of culture.
  • the object of the present invention is to prepare a large amount of dendritic cells, more dendritic cells can be obtained when the period of culturing in a medium containing GM-CSF and SCF is 2 to 5 weeks. This is advantageous. On the other hand, when the culture period is less than 2 weeks and exceeds 5 weeks, the number of dendritic cells obtained may not be sufficient.
  • CD11c positive cells increase until 3 weeks after the start of culture in a medium containing GM-CSF and SCF, but the growth rate decreases after 4 weeks. . Therefore, the trade-off between obtaining a larger amount of dendritic cells and obtaining dendritic cells in a shorter period of time is that the growth in a medium containing GM-CSF and SCF is necessary for the therapeutic effect.
  • the number of dendritic cells approximately 10 9
  • the proliferation rate decreases and the number of precursor cells of dendritic cells does not increase even when cultured in a medium containing GM-CSF and SCF. It is time to become.
  • the culture period in the step of culturing the cells in a medium containing GM-CSF and SCF may be 2 to 5 weeks, more preferably 2 to 3 weeks.
  • the culture period in the step of culturing the cells in the medium containing GM-CSF and IL-4 after switching from the medium containing GM-CSF and SCF to the medium containing GM-CSF and IL-4 is as follows. It may be 2 days to 14 days, and more preferably 2 days to 7 days.
  • the mononuclear cell population separated from the collected blood cell population may be once stored frozen and then thawed at a preferred timing for use in the next step.
  • the remaining mononuclear cell population is cryopreserved, and then at a preferred timing. It may be melted and used for the next step.
  • a bun bunker (trademark) manufactured by Lymphoctech Co., Ltd., other commercially available cell cryopreservation solutions or self-prepared cell cryopreservation solutions may be used.
  • Dendritic cells prepared by the method of the present invention were stimulated with pro-inflammatory mediators such as OK-432, TNF- ⁇ , IL-1 ⁇ , IL-6, and PGE 2 to acquire T cell stimulating ability. Later, it may be transplanted into the patient.
  • pro-inflammatory mediators such as OK-432, TNF- ⁇ , IL-1 ⁇ , IL-6, and PGE 2 to acquire T cell stimulating ability. Later, it may be transplanted into the patient.
  • pro-inflammatory mediators such as OK-432, TNF- ⁇ , IL-1 ⁇ , IL-6, and PGE 2
  • PGE 2 pro-inflammatory mediators
  • PAP prostate acid phosphatase
  • tumor antigen MAGE-A3 tumor antigen MAGE-A3
  • cancer testis antigen NY-ESO-1 respectively.
  • For the treatment of a single cancer combine dendritic cells that are individually stimulated with multiple cancer-specific antigens, or use dendritic cells that are simultaneously stimulated with multiple cancer-specific antigens. In some cases.
  • the dendritic cells prepared by the method of the present invention may be further prepared as a pharmaceutical composition (including regenerative medicine products such as cellular pharmaceutical compositions) for the treatment of diseases.
  • an agent for other therapy such as a chemotherapeutic agent or a radiation therapy agent, may be combined with the dendritic cells prepared by the method of the present invention.
  • Such drugs include recombination of agents that suppress the growth of cancer cells such as CDDP, TS-1, and Gemzar, and factors that enhance the activity of cytotoxic T cells that attack cancer cells such as IL-12p70 and PGE2. Examples include, but are not limited to, inhibitors for proteins and factors that suppress the activity of cytotoxic T cells such as IL-10, such as antibodies and short interfering RNAs.
  • the pharmaceutical composition containing dendritic cells prepared by the method of the present invention may contain a pharmaceutically acceptable carrier.
  • the carrier include any solution capable of suspending living cells, such as physiological saline, phosphate buffered saline (PBS), medium, serum, and the like.
  • an immunogenicity enhancing agent may be used in combination in order to enhance immunogenicity.
  • the immunogenicity enhancer include immunostimulators such as cytokines, bacterial toxins, and Mycobacterium tuberculosis cell components, and alum, Freund's adjuvant, and other adjuvant agents.
  • Peripheral blood collection Peripheral blood was collected from healthy volunteer subjects. This experiment was conducted with the approval of the Kyushu University Medical District Department Clinical Research Ethics Review Committee (approval date: August 21, 2013), and written consent was obtained from the volunteer subjects. Yes. Blood collection was performed using a vacuum blood collection tube (TERUMO Venoject II EDTA-2Na) equipped with a 22-23G needle, or by apheresis.
  • TERUMO Venoject II EDTA-2Na equipped with a 22-23G needle, or by apheresis.
  • the obtained blood was diluted 2-fold with diluent 1 (D-PBS) kept at room temperature, and 20 mL to 30 mL of diluted blood was added to 20 mL of Ficoll Paque in each centrifuge tube. Overlaid with PLEMIUM (specific gravity 1.077). Centrifugation was performed at 500 ⁇ g for 20 minutes at room temperature and stopped without braking. The centrifugal supernatant (plasma part) was removed leaving a few mL, and the intermediate layer was recovered. The intermediate layer collected from one or two centrifuge tubes was collected in one new centrifuge tube, the volume was adjusted to 50 mL with the diluent 1, and centrifugation was further performed twice.
  • D-PBS diluent 1
  • PLEMIUM specific gravity 1.077
  • Diluent 2 PBS to which 2 mM EDTA and 2% fetal calf serum were added
  • CD3-expressing cells, CD19-expressing cells, and CD56-expressing cells Anti-CD3 antibody, anti-CD19 antibody, or magnetic beads with immobilized anti-CD56 antibody (CD3 microbeads, human, Cat. No. 130-050) CD19 microbeads, human, Cat.no.130-050-301; CD56 microbeads, human, Cat.no.130-050-401 (Milteny Biotech KK)) Added to the suspension. The mononuclear cell suspension containing the beads was allowed to stand at 4 ° C. for 15 minutes.
  • the magnetic beads are separated from the suspension by an LD column and a manual cell separator, and cells expressing CD3 on the surface (CD3 expressing cells), cells expressing CD19 on the surface (CD19 expressing cells), and Cells expressing CD56 on the surface (CD56 expressing cells) were removed.
  • FIG. 2 shows the results of examining the composition of the mononuclear cell population after separation by Ficoll and the composition of the mononuclear cell population after removing CD3-expressing cells, CD19-expressing cells, and CD56-expressing cells by the flow cytometry method. It was shown to.
  • CD3 - CD19 - CD56 - cells The cells remaining in the suspension (hereinafter referred to as “CD3 - CD19 - CD56 - cells”) were 10 ng / mL.
  • IMDM hereinafter referred to as “GM” to which recombinant human GM-CSF, 5 ng / mL recombinant human SCF, 10% fetal bovine serum, and antibiotics (penicillin G100 units / mL, streptomycin sulfate 100 ⁇ g / mL) were added.
  • EZ-BindShut (registered trademark) SP coated with a fluoropolymer containing polymerized units based on a monomer having a biocompatible group and diluted with a biocompatible group) AGC Techno Glass Co., Ltd.
  • New Coat raw material containing 2-methacryloyloxyethyl phosphorylcholine (MPC) Low-adsorption cell culture vessel with compatible polymer coating (EZ-Bindshut (registered trademark) II, AGC Techno Glass Co., Ltd., 6-well plate) (hereinafter referred to as “MPC”), and surface treated by corona discharge treatment
  • MPC 2-methacryloyloxyethyl phosphorylcholine
  • Dendritic cell maturation by switching medium After CD3 ⁇ CD19 ⁇ CD56 ⁇ cells are cultured in the GM / SCF medium for 3 weeks in New Coat, MPC, Adhesion, the precursor cells of dendritic cells are differentiated into dendritic cells. The medium was switched to make it happen.
  • the new medium is CellGro (registered trademark) DC Medium (hereinafter referred to as "GM / IL-4 medium”) supplemented with 50 ng / mL recombinant human GM-CSF and 50 ng / mL recombinant human IL-4. )), 3 weeks after the start of the culture, the GM / SCF medium was switched to the GM / IL-4 medium, and the culture was further continued for 1 week.
  • GM / IL-4 medium CellGro (registered trademark) DC Medium
  • Dendritic Cell Differentiation Markers CD3 ⁇ CD19 ⁇ CD56 ⁇ cells 4 weeks after the start of culture were subjected to CellGro DC added with OK-432 (hereinafter referred to as “OK” in order to examine the response to stimulation by OK-432. -432 medium ”) and further cultured overnight.
  • the cells were subjected to analysis by a flow cytometry method according to a conventional method for measuring dendritic cell differentiation markers.
  • the cell surface markers used were CD11c, HLA-ABC, CD83, CD80, CD86, and HLA-DR.
  • FIG. 3 is a growth curve of cells obtained by culturing CD3 ⁇ CD19 ⁇ CD56 ⁇ cells with New Coat, MPC, and Adhesion, respectively. In either case, the number of cells increased in the GM / SCF medium for 3 weeks and continued to increase until switched to GM / IL-4 medium.
  • CD11c positive rate transition during amplification culture period (day 0-29) In the cells at the start of culture (day 0), the proportion of CD11c-positive and CD14-positive cells in the cell population from which CD3, CD19, and CD56-expressing cells on day 0 of culture were removed was 52.3% (common to each group). .
  • CD11c-positive and CD14-positive cells are dendritic cells or their precursor cells. As these cultures continue in the GM / SCF medium, CD14 gradually becomes negative.
  • the CD11c positive rate transition during the amplification culture period (day 0 to 29) was monitored. In all cases, the positive rate decreased slightly from the second week to the third week of culture in GM / SCF medium. Although it was observed, after switching to GM / IL-4 medium, the positive rate increased to about 90% by culturing for 1 week (ie, at day 29) (data not shown).
  • FIG. 4 Transition of cell number during amplification culture period (day 0 to 29) shows the transition of the number of CD11c positive cells during the amplification culture period.
  • FIG. 5 shows the amplification factor of the number of CD11c positive cells during day 0 to 29. Is shown. In any case, the number of CD11c positive cells was determined at the start of culture, the total number of cells at the 7th day, the 14th day, the 21st day, the 28th day, and the 29th day. Calculated as the product of the percentage of CD11c positive cells.
  • the number of CD11c positive cells continued to increase until the third week in the order of New Coat, Adhesion, and MPC, and became 10.7 times, 9.4 times, and 7.0 times from the beginning of the culture at the third week stage, respectively. . Then, when switching to GM / IL-4 medium and entering the differentiation induction stage of dendritic cell precursor cells into dendritic cells, the increase rate decreases or stops, and the final number of CD11c positive cells is New Coat, MPC. , 13.3 times, 11.9 times, and 4.6 times in the order of Adhesion.
  • Adhesion may have hindered proliferation and / or differentiation of dendritic cells per se due to the effect of cell adhesion to the culture vessel, or may have caused proliferation of cells other than dendritic cells.
  • the coating of the culture vessel is important, and it was considered that the culture vessel provided with the low cell adsorption coating, particularly the coating by “New Coat” was most suitable.
  • FIGS. 6 and 7 are graphs comparing flow cytometry analysis results of cell surface markers of cells cultured in New Coat, MPC, and Adhesion.
  • the cells used for the analysis were prepared by switching from GM / SCF medium to GM / IL-4 medium 3 weeks after the start of culture, further culturing for 1 week, and then culturing overnight in OK-432 medium. It was.
  • FIGS. 6 and 7 in New Coat, expression was confirmed for both CD83 and CD86, which are known to increase in expression when dendritic cells differentiate.
  • CD83 and CD86 which are known to increase in expression when dendritic cells differentiate.
  • HLA molecules forming a complex with antigen fragments were also expressed without problems. From this, it was shown that the cell prepared by New Coat expresses a differentiation marker as a dendritic cell and has a function as an antigen-presenting cell.
  • the method of the present invention it is possible to dramatically increase the number of dendritic cells as compared with the prior art. That is, by using the method of the present invention, it becomes easier to secure the number of dendritic cells for use in dendritic cell transplantation therapy. In addition, by using the method of the present invention, a certain number of dendritic cells can be obtained in a shorter period of time, and earlier treatment is possible for patients who need dendritic cell transplantation therapy. In dendritic cell transplantation therapy, the preparation of dendritic cells used for treatment becomes a bottleneck, so the necessary amount of dendritic cells can be prepared as soon as possible, especially for patients who require early treatment. Can be a great advantage in therapy.
  • the culture vessel used in the method of the present invention has less adhesion of dendritic cells to the culture vessel as compared with the conventional culture vessel, if the method of the present invention is used, it exceeds the value shown as actual data. Many dendritic cells can be recovered. Furthermore, if the method of the present invention is used, damage to cells due to detachment from the culture vessel can be reduced, and thus more normal (or higher biological activity) dendritic cells can be recovered.

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention a pour objet de fournir un procédé destiné à obtenir une grande quantité de cellules arborescentes à partir de cellules sanguines prélevées chez un sujet. Plus précisément, l'invention fournit un procédé de préparation de population de cellules arborescentes qui inclut : (a) une étape au cours de laquelle une population de mononucléaires provenant d'une population de cellules sanguines prélevées, est séparée ; (b) une étape au cours de laquelle une population de cellules exprimant un CD3 à la surface des cellules, est retirée de la population de mononucléaires séparée à ladite étape (a) ; et (c) une étape au cours de laquelle la population de mononucléaires obtenue à ladite étape (b), est cultivée dans un milieu contenant un ＧＭ－ＣＳＦ et un ＳＣＦ à l'aide d'un réceptacle de culture revêtu d'un nouvel agent de revêtement.
PCT/JP2017/025207 2016-07-12 2017-07-11 Procédé de préparation de population de cellules arborescentes Ceased WO2018012479A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-137584 2016-07-12
JP2016137584A JP2018007599A (ja) 2016-07-12 2016-07-12 樹状細胞集団の調製方法

Publications (1)

Publication Number Publication Date
WO2018012479A1 true WO2018012479A1 (fr) 2018-01-18

Family

ID=60951788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/025207 Ceased WO2018012479A1 (fr) 2016-07-12 2017-07-11 Procédé de préparation de population de cellules arborescentes

Country Status (2)

Country Link
JP (1) JP2018007599A (fr)
WO (1) WO2018012479A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055900A1 (fr) * 2008-11-14 2010-05-20 ディナベック株式会社 Procédé de fabrication de cellules dendritiques
JP2011239701A (ja) * 2010-05-14 2011-12-01 Tella Inc 樹状細胞の培養方法
JP2012219062A (ja) * 2011-04-08 2012-11-12 Univ Of Tokyo 細胞傷害性ｔ細胞誘導用組成物
JP2015513401A (ja) * 2012-03-02 2015-05-14 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 樹状細胞ワクチンの調製方法
WO2016002796A1 (fr) * 2014-06-30 2016-01-07 旭硝子株式会社 Inhibiteur d'adhérence de protéines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055900A1 (fr) * 2008-11-14 2010-05-20 ディナベック株式会社 Procédé de fabrication de cellules dendritiques
JP2011239701A (ja) * 2010-05-14 2011-12-01 Tella Inc 樹状細胞の培養方法
JP2012219062A (ja) * 2011-04-08 2012-11-12 Univ Of Tokyo 細胞傷害性ｔ細胞誘導用組成物
JP2015513401A (ja) * 2012-03-02 2015-05-14 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 樹状細胞ワクチンの調製方法
WO2016002796A1 (fr) * 2014-06-30 2016-01-07 旭硝子株式会社 Inhibiteur d'adhérence de protéines

Also Published As

Publication number Publication date
JP2018007599A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
JP5572863B2 (ja) Ｎｋ細胞の増幅方法
JP5954918B2 (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
CN103597072B (zh) 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法
JP2009518045A5 (fr)
JP5856025B2 (ja) 単球またはｎｋ細胞を入手する方法
TW201435087A (zh) 含免疫細胞之組成物的製造方法及癌症治療用組成物
JP2017061558A (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
JP5989016B2 (ja) Ｎｋ細胞の増幅方法
AU2012255112A1 (en) Mesenchymal stromal cell populations and methods of making same
EP2710121A1 (fr) Population de cellules stromales mésenchymateuses et procédés de fabrication associés
CN107849537A (zh) 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
CN105452449B (zh) 来自异源供体的单核细胞的共分化
JP2002528115A (ja) ＴｃＲγδＴ細胞の生産方法
KR101440102B1 (ko) 하이드로젤 코팅과 전기천공법을 이용한 강력한 항원제시세포의 제조방법
JP6088633B2 (ja) 樹状細胞の培養方法
JP2011239701A (ja) 樹状細胞の培養方法
WO2018012479A1 (fr) Procédé de préparation de population de cellules arborescentes
JP6426767B2 (ja) 樹状細胞の培養方法
JP2013081428A (ja) Ｃｄ５６陽性ｔ細胞増強方法
US20070154877A1 (en) Method for the direct culture of dendritic cells without a preceding centrifugation step
JP2014111631A (ja) 樹状細胞の培養方法
EP3556851B1 (fr) Procédé de production d'une cellule dendritique stimulant les lymphocytes t tueurs naturels (nkt) et procédé de préparation d'une composition cellulaire contenant une cellule dendritique stimulant les lymphocytes nkt et lymphocyte nkt
WO2012160200A1 (fr) Cellules dendritiques tolérogènes et leur utilisation en thérapie cellulaire
EP1795589A1 (fr) Procédés directs pour la culture de cellules dendritiques sans étape de centrifugation
HK1194101B (zh) 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17827606

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17827606

Country of ref document: EP

Kind code of ref document: A1